FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

vvasimigton, D.C. 2004

l	OMB APPROVAL									
l	OMB Number:	3235-0287								
l	Estimated average burde	en								
l	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* ROSS BRUCE						2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC [BIIB]									icable)	g Pers	son(s) to Issu	
(Last) (First) (Middle) 14 CAMBRIDGE CENTER							f Earl 004	iest Tran:	saction (N	/lonth	n/Day/Year)		Office	Director Officer (give title below)		Other (s below)	·	
(Street) CAMBRIDGE MA 02142 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tab	ole I - N	on-Deri	ivativ	e Se	curit	ties Ac	quired	, Di	sposed o	f, or Be	neficial	ly Owne	d			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)					Execution Date,			3. Transac Code (II 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			Benefic Owned	ies cially Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Price	Report Transa (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 11/19/20					/2004	004			M		15,000	A	\$31.08	33 30	0,000		D	
Common Stock 11/19/20					/2004	004		S		15,000	D	\$55.9	1 1	5,000		D		
			Table II								posed of, convertil			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	n Date,	4. Transa Code (8)				6. Date E Expiration (Month/E	n Da		of Securities		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Amount or Number of Shares					
Stock Option (right-to-	\$31.0833	11/19/2004			M			15,000	(2)		01/03/2010	Common Stock	15,000	(1)	15,00	0	D	

Explanation of Responses:

- 1. Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC rule 16(b)-3(d).
- $2.\ Immediately\ exercisable\ for\ all\ the\ option\ shares\ on\ grant\ date\ of\ 1/3/2000\ subject\ to\ Issuer's\ repurchase\ rights\ which\ lapsed\ on\ 1/3/2001.$

Remarks:

By: Benjamin S. Harshbarger; For: Bruce R. Ross

11/23/2004

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

I, the undersigned, a director and/or an executive officer of Biogen Idec Inc., hereby authorize and designate Thomas J. Bucknum, Anne Marie Cook, Jo Ann Taormina, and Benjamin S. Harshbarger and each of them acting alone, as my attorney-in-fact to execute and file on my behalf any and all Forms 3, 4 and 5 (including any amendments thereto) that I may be required to file with the United States Securities and Exchange Commission as a result of my ownership of or transactions in securities of Biogen Idec Inc. The authority granted under this power of attorney shall continue for so long as I am required to file Forms 3, 4 and 5 with regard to my ownership of or transactions in securities of Biogen Idec Inc., unless earlier revoked in writing, but shall terminate automatically as to each individual attorney-in-fact when such person is no longer an employee of Biogen Idec Inc. I acknowledge that the attorneys-in-fact appointed hereunder are not assuming, nor is Biogen Idec Inc. assuming, any of my responsibility to comply with Section 16 of the Securities Exchange Act of 1934.

IN WITNESS WHEREOF, the undersigned has caused this instrument to be duly executed this 25th day of January, 2004.

/S/ Bruce R. Ross Bruce

R. Ross